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Aortic dissection is a potentially fatal but rare disease characterized by an aortic intimal tear with blood passing into the media
creatingafalselumenandwithresultanthighmortalitydependingonthelocationofdissectionifnotaggressivelytreated.Cocaine
users are known to have a higher incidence of aortic dissection. We report here aortic dissection in a patient with cocaine abuse
which did not respond to traditional medication regimes used currently in this setting. Worth mentioning is the use of an alpha-
2 receptor selective agonist named Dexmedetomidine as a treatment modality to control hypertension in this patient, which is
approved only for sedation of intubated and mechanically ventilated patients in the intensive care settings and for sedation during
invasive procedures. This paper illustrates the practical beneﬁcial role of Dexmedetomidine in controling blood pressure in the
settings of cocaine-induced sympathetic surge when other treatment modalities fail.
1.Introduction
Aortic dissection is a potentially fatal but rare disease char-
acterized by an aortic intimal tear with blood passing into
the media creating a false lumen. Cocaine users are known
to have a higher incidence of aortic dissection [1]. Aggressive
blood pressure reduction is the paradigm of aortic dissection
management [2, 3]. We present a case report of the use of
dexmedetomidine, a selective alpha-2 agonist, as an antihy-
pertensive and sedative agent in a female with acute aortic
dissection after crack cocaine who was refractory to tradi-
tional interventions.
2.CaseReport
A 45-years-old woman brought in by EMS after she was
found in distress on a subway platform. The patient with
knownhistoryofdiabetestypeIIandhypertensionpresented
with stabbing chest pain radiating to the interscapular region
after crack cocaine use. In addition to the chest pain and
diaphoresis, the patient also complained of progressive pain
and cold sensation over left lower extremity. Upon physical
examination, the patient was noted to be agitated and com-
bative with a blood pressure (BP) of 205/147mmHg, a heart
rate of 77 beats per minute, 17 respirations per minute,
and was afebrile. Initial cardiovascular exam was positive for
an S4 gallop and absent left lower extremity pulses. Lung
examination was unremarkable. Initial management con-
sisted of intravenous administration of a total of 9mg
of Lorazepam and 35mg of Labetalol without acceptable
reduction in BP. In addition to further Lorazepam, Labetolol
later Esmololol infusions, IV Nitroglycerin was started and
quickly titrated to 200mcg/kg/hr but acceptable blood pres-
sure reduction of blood pressure was still not achieved on
this regimen (Table 1). A contrast-enhanced Computerized
Tomography (CECT) of the thorax, abdomen, and pelvis2 Case Reports in Medicine
Table 1
Time PM BP mm Hg Nitroglycerine
mcg/kg/hr
Esmolol
mcg/kg/hr Lorazepam Labetalol
mg/hr
Dexmedetomidine
mcg/kg/hr Sedation level
3:15 214/129 100 230 2mg IVP — — 0
3:25 100 230 2mg IVP — — 0
3:30 215/120 100 230 2mg IVP — — 0
3:35 100 230 2mg/hr — — 0
3:45 194/120 100 230 2mg/hr 30 — 0
4:00 184/109 200 Oﬀ 4mg/hr 60 — 0-1
4:15 164/94 200 Oﬀ 4mg/hr 60 50mcg bolus 1-2
4:30 109/52 Oﬀ Oﬀ 4mg/hr Oﬀ 0.1 1-2
4:45 118/70 Oﬀ Oﬀ Oﬀ Oﬀ 0.1 1-2
5:00 121/70 Oﬀ Oﬀ Oﬀ Oﬀ 0.1 1-2
5:15 123/71 Oﬀ Oﬀ Oﬀ Oﬀ 0.1 1-2
5:30 132/78 Oﬀ Oﬀ Oﬀ Oﬀ 0.1 1-2
conﬁrmed a Stanford Type B aortic dissection beginning just
beyond the left subclavian artery and extending to the iliac
bifurcation. Upon arrival to the Cardiac Care Unit, decision
was made to begin an infusion of Dexmedetomidine since
all other therapies continued to be unsuccessful. The alpha 2
stimulation provided by the Dexmedetomidine was hypoth-
esized to decrease the eﬀects of the adrenergic surge induced
by the cocaine thus mitigating alpha 1 and beta-receptor
stimulation. Within 10 minutes of Dexmedetomidine bolus
and continuous infusion, adjunct antihypertensive and seda-
tive infusions were quickly weaned oﬀ. Evolving signs of
ischemia in the left lower extremity warranted emergent
femoral-femoral bypass. Vascular surgery team performed
procedure successfully and uneventfully. Postoperatively BP
control was maintained with Dexmedetomidine and Nitro-
glycerin then Nicardipine uneventfully. The total duration
of Dexmedetomidine therapy was 42 hours. The patient was
transitioned to oral antihypertensives simultaneously. The
clinical course evolved without any further complications,
and the patient was discharged after 14 days.
3. Discussion
Acute aortic dissection is a life-threatening disease with esti-
mated incidence of 2.6 to 3.5 per 100,000 person-years [4–
6]. The incidence is higher in certain populations including
patients suﬀering from Marfan’s syndrome and cocaine users
[7]. Crack cocaine abuse accounts for up to 37 percent
of dissections amongst select populations [8, 9]. Inhibition
of norepinephrine reuptake by cocaine within peripheral
sympathetic nerve synaptic clefts leads to a sympathetic
surge within cutaneous and skeletal muscle beds [10–15].
The end result is an increase in peripheral vasoconstriction
and tachycardia, which causes an increase in aortic shearing
forces and in turn increases the risk for intimal rupture.
Intuitively, reduction of aortic shearing forces is a basic
tenetofacuteaorticdissectionmanagement.Thestimulation
of alpha-2 adrenergic receptors by Dexmedetomidine and
Clonidine in the medullary vasomotor center reduces Nore-
pinephrine turnover thus decreasing central sympathetic
outﬂow. These pharmacologic interventions also increase
parasympathetic outﬂow and inhibit sympathetic outﬂow
from the locus coerulous which allows for increased stim-
ulation of inhibitory neurons including the gamma amino
butyric acid (GABA) system. GABA promotes sedation and
analgesia, decreases minimum alveolar concentration of
inhalational anesthetic needs, blunts sympathetic nervous
response to noxious stimuli, and decreases blood pressure
and heart rate [16–19]. Dexmedetomidine is FDA approved
for sedation of intubated and mechanically ventilated
patients in the intensive care setting and for sedation during
invasive procedures. Recently, there have been several cases
of “oﬀ label” use of Dexmedetomidine for patients who
were found to fail traditional weaning procedures as the
sedative eﬀects of Dexmedetomidine have the beneﬁt of not
suppressing respiratory drive. Clonidine, another alpha-2
receptoragonist,andinsomecasereportsDexmedetomidine
have been explored for cocaine and opiate withdrawal and
detoxiﬁcation [19–30]. There are also some experimental
data demonstrating Clonidine’s eﬀect in blunting cocaine-
induced hypertension [31]. In the same manner, there is one
study that demonstrated that concomitant administration of
Dexmedetomidine along with cocaine to healthy volunteers
blunted its sympathomimetic eﬀects; however, our search of
the literature did not yield any reports of the clinical appli-
cation of Dexmedetomidine speciﬁcally for cocaine-induced
hypertension or even hypertension itself.
Compared to Clonidine, Dexmedetomidine has multiple
advantages. Dexmedetomidine is 8 times more alpha-2 se-
lective than Clonidine [32], has a shorter half-life (2-3 hours
versus 12–24 hour), and is equally eﬃcacious in Caucasians
and African Americans; Clonidine has been shown to be
less eﬀectiveinAfricanAmericans[33]. These characteristics
make Demedetomidine a suitable drug for the continu-
ous intravenous infusion and a better alpha-2 adrenergic
agent for the treatment of cocaine-induced hypertension.
Furthermore, Dexmedetomidine may even have a role inCase Reports in Medicine 3
noncocaine-induced hypertensive urgencies and emergen-
cies or as an overall Clonidine substitute. However, some
caution is advised in using Dexmedetomidine. Though it is
a selective alpha-2 agonist, in higher doses it may result in
hypertension due to alpha-1 stimulation that in the usual
dose range is uncommon [34] and was not observed prac-
tically in our patient.
4. Conclusion
In conclusion, this paper demonstrates that Dexmedetomi-
dine can be used in cocaine-induced hypertensive aortic dis-
section management secondary to its dual properties of re-
ducing blood pressure and heart rate in addition to its seda-
tive and analgesic properties which directly address cocaine-
induced anxiety and dissection-related pain that further
contribute to the adrenergic surge. This paper provides a
practical insight that Dexmedetomidine can be considered
as a therapeutic agent to address sympathomimetic conse-
quences of acute cocaine ingestion and related hypertensive
crisis, and possible other hypertensive situations though data
is limited to date and needs further exploration.
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